We recently compiled a list of the Best Medical Stocks To Buy Under $20. In this article, we are going to take a look at ...

The dual T-cell agonist invikafusp alfa achieved a 50% DCR in heavily pretreated anti–PD-1/PD-L1–resistant tumors, per findings at the 2024 SITC Annual Meeting.

Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report) have been given a consensus rating of “Buy” by the eleven analysts that are presently covering the firm, Marketbeat.com reports.